Prestige BioPharma Limited (KRX:950210)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,850
-120 (-0.93%)
Dec 30, 2025, 3:30 PM KST
-9.51%
Market Cap154.45B
Revenue (ttm)14.41B
Net Income (ttm)15.76B
Shares Out12.02M
EPS (ttm)262.37
PE Ratio48.98
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume41,642
Average Volume121,026
Open13,040
Previous Close12,970
Day's Range12,690 - 13,150
52-Week Range11,000 - 20,000
Beta0.97
RSI49.20
Earnings DateFeb 27, 2026

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Singapore
Stock Exchange Korea Stock Exchange
Ticker Symbol 950210
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.